AIM： To determine the effects of pentoxifylline （PTX） on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome （HPS） in chil- dren. METHODS： In a pilot study of 10 children wit...AIM： To determine the effects of pentoxifylline （PTX） on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome （HPS） in chil- dren. METHODS： In a pilot study of 10 children with chronic liver disease, who had HPS, 20 mg/kg/d PTX was ad- ministered for 3 mo. Clinical data and arterial blood gas parameters were evaluated at baseline, the end of the treatment period, and 3 mo after drug discontinuation. RESULTS： Six patients could tolerate PTX, while four patients experienced complications, Among patients who could tolerate PTX, there was a significant increase in arterial oxygen pressure （PaO2） （P = 0,02） and oxy- gen saturation （Sa02） （P = 0.04） and alveolar-arterial oxygen gradient （P = 0.02） after 3 mo of treatment. Significant decreases in Pa02 （P = 0.02） and alveolararterial oxygen gradient （P = 0.02） were also seen after drug discontinuation. CONCLUSION： PTX may improve PaO2, Sa02 and alve- olar-arterial oxygen gradient in the early stage of HPS.展开更多
Psoriasis is a potentially debilitating inflammatory dermatosis affecting 0.2%-4.8% of the population worldwide causing a significant occupational, personal or psychosocial morbidity to these patients for life. The ba...Psoriasis is a potentially debilitating inflammatory dermatosis affecting 0.2%-4.8% of the population worldwide causing a significant occupational, personal or psychosocial morbidity to these patients for life. The basic aim of psoriasis therapy is to control the disease to maximum possible extent and improve the patient's quality of life. Management of triggers for flareups, lifestyle modifications, and dietary supplements are often recommended. Intermittent or rotational therapy with frequent alterations in treatment options is usually needed to reduce toxicity of anti-psoriatic drugs in the absence of safer alternatives. Currently, several biological agents categorized as either T-cell targeted(e.g., Alefacept, Efalizumab) or cytokine modulating(e.g., Adalimumab, Infliximab, Etanercept) are available for treating severe psoriasis. However, their high cost is often precluding for most patients. The usefulness of systemic(methotrexate, cyclosporine, acitretin or several other therapeutic agents) or topical(tar, anthralin, corticosteroids or calcipotriol ointments, phototherapy with or without psoralens) therapies has been well established for the management of psoriasis. The literature is also replete with benefits of less used non-standard and unconventional treatment modalities(hydroxycarbamide, azathioprine, leflunomide, mycophenolate mofetil, isotretinoin, fumarates, topical calcineurin inhibitors, peroxisome proliferator-activated receptors agonists, statins, sulfasalazine, pentoxifylline, colchicine, grenz ray therapy, excimer laser, climatotherapy and balneophototherapy, peritoneal dialysis, tonsillectomy, ichthyotherapy, etc.). These can be used alternatively to treat psoriasis patients who have mild/minimal lesions, are intolerant to conventional drugs, have developed side effects or achieved recommended cumulative dose, where comorbidities pose unusual therapeutic challenges, or may be as intermittent, rotational or combination treatment alternatives.展开更多
基金Supported by Research Council of Mashhad University of Medical Sciences
文摘AIM： To determine the effects of pentoxifylline （PTX） on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome （HPS） in chil- dren. METHODS： In a pilot study of 10 children with chronic liver disease, who had HPS, 20 mg/kg/d PTX was ad- ministered for 3 mo. Clinical data and arterial blood gas parameters were evaluated at baseline, the end of the treatment period, and 3 mo after drug discontinuation. RESULTS： Six patients could tolerate PTX, while four patients experienced complications, Among patients who could tolerate PTX, there was a significant increase in arterial oxygen pressure （PaO2） （P = 0,02） and oxy- gen saturation （Sa02） （P = 0.04） and alveolar-arterial oxygen gradient （P = 0.02） after 3 mo of treatment. Significant decreases in Pa02 （P = 0.02） and alveolararterial oxygen gradient （P = 0.02） were also seen after drug discontinuation. CONCLUSION： PTX may improve PaO2, Sa02 and alve- olar-arterial oxygen gradient in the early stage of HPS.
文摘Psoriasis is a potentially debilitating inflammatory dermatosis affecting 0.2%-4.8% of the population worldwide causing a significant occupational, personal or psychosocial morbidity to these patients for life. The basic aim of psoriasis therapy is to control the disease to maximum possible extent and improve the patient's quality of life. Management of triggers for flareups, lifestyle modifications, and dietary supplements are often recommended. Intermittent or rotational therapy with frequent alterations in treatment options is usually needed to reduce toxicity of anti-psoriatic drugs in the absence of safer alternatives. Currently, several biological agents categorized as either T-cell targeted(e.g., Alefacept, Efalizumab) or cytokine modulating(e.g., Adalimumab, Infliximab, Etanercept) are available for treating severe psoriasis. However, their high cost is often precluding for most patients. The usefulness of systemic(methotrexate, cyclosporine, acitretin or several other therapeutic agents) or topical(tar, anthralin, corticosteroids or calcipotriol ointments, phototherapy with or without psoralens) therapies has been well established for the management of psoriasis. The literature is also replete with benefits of less used non-standard and unconventional treatment modalities(hydroxycarbamide, azathioprine, leflunomide, mycophenolate mofetil, isotretinoin, fumarates, topical calcineurin inhibitors, peroxisome proliferator-activated receptors agonists, statins, sulfasalazine, pentoxifylline, colchicine, grenz ray therapy, excimer laser, climatotherapy and balneophototherapy, peritoneal dialysis, tonsillectomy, ichthyotherapy, etc.). These can be used alternatively to treat psoriasis patients who have mild/minimal lesions, are intolerant to conventional drugs, have developed side effects or achieved recommended cumulative dose, where comorbidities pose unusual therapeutic challenges, or may be as intermittent, rotational or combination treatment alternatives.
